Literature DB >> 1698864

HLA-DR2a is the dominant restriction molecule for the cytotoxic T cell response to myelin basic protein in DR2Dw2 individuals.

D Jaraquemada1, R Martin, S Rosen-Bronson, M Flerlage, H F McFarland, E O Long.   

Abstract

The HLA-DR2 restriction of the T cell response to myelin basic protein (MBP) was studied using murine L cells transfected with DRalpha and either DR2a or DR2b beta-chain cDNA. DR2a and DR2b represent the two isotypic DRbeta chains expressed in DR2Dw2 haplotypes. Eleven MBP-specific cytolytic T cell lines derived from patients with multiple sclerosis were isolated. Two of these cell lines recognized MBP-pulsed DR2-expressing L cell transfectants and four of them could only recognize the L cells if the adhesion molecule ICAM-1 was expressed in addition to HLA-DR2. Five of the six lines were restricted by HLA-DR2a; one line recognized Ag in conjunction with DR2b, but only if ICAM-1 was coexpressed. The remaining five lines did not lyse MBP-pulsed L cells. The ability of the DR2b molecules on transfected cells to stimulate T cells was confirmed with DR2b-allospecific T cell clones. Although five MBP-specific lines were restricted by DR2a, they recognized different parts of the MBP molecule, as demonstrated by the presentation of shorter peptides. Thus, our results suggest that DR2a is a dominant restriction molecule in MBP-specific responses by DR2+ MS patients. The results also indicate that the reported heterogeneity in MBP epitopes recognized by DR2-restricted T cells, may not be due to the use of different restriction elements but rather to the binding of different MBP peptides to DR2a molecules.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698864

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  Role of leukotrienes in bronchial hyperresponsiveness and cellular responses in airways.

Authors:  A R Leff
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 2.  Antigen-specific therapies for the treatment of autoimmune diseases.

Authors:  D A Hafler; H L Weiner
Journal:  Springer Semin Immunopathol       Date:  1995

3.  Increased frequencies of myelin oligodendrocyte glycoprotein/MHC class II-binding CD4 cells in patients with multiple sclerosis.

Authors:  Khadir Raddassi; Sally C Kent; Junbao Yang; Kasia Bourcier; Elizabeth M Bradshaw; Vicki Seyfert-Margolis; Gerald T Nepom; William W Kwok; David A Hafler
Journal:  J Immunol       Date:  2011-06-08       Impact factor: 5.422

4.  Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types.

Authors:  J A Berzofsky; C D Pendleton; M Clerici; J Ahlers; D R Lucey; S D Putney; G M Shearer
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

5.  Complementary mutations in an antigenic peptide allow for crossreactivity of autoreactive T-cell clones.

Authors:  L J Ausubel; C K Kwan; A Sette; V Kuchroo; D A Hafler
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

6.  Reassessing the role of HLA-DRB3 T-cell responses: evidence for significant expression and complementary antigen presentation.

Authors:  Rosa Faner; Eddie James; Laurie Huston; Ricardo Pujol-Borrel; William W Kwok; Manel Juan
Journal:  Eur J Immunol       Date:  2010-01       Impact factor: 5.532

7.  Myelin basic protein-specific TCR/HLA-DRB5*01:01 transgenic mice support the etiologic role of DRB5*01:01 in multiple sclerosis.

Authors:  Jacqueline A Quandt; Jaebong Huh; Mirza Baig; Karen Yao; Naoko Ito; Mark Bryant; Kazuyuki Kawamura; Clemencia Pinilla; Henry F McFarland; Roland Martin; Kouichi Ito
Journal:  J Immunol       Date:  2012-08-10       Impact factor: 5.422

8.  Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones.

Authors:  E Meinl; F Weber; K Drexler; C Morelle; M Ott; G Saruhan-Direskeneli; N Goebels; B Ertl; G Jechart; G Giegerich
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

9.  A strategy to determine HLA class II restriction broadly covering the DR, DP, and DQ allelic variants most commonly expressed in the general population.

Authors:  Denise M McKinney; Scott Southwood; Denise Hinz; Carla Oseroff; Cecilia S Lindestam Arlehamn; Veronique Schulten; Randy Taplitz; David Broide; Willem A Hanekom; Thomas J Scriba; Robert Wood; Rafeul Alam; Bjoern Peters; John Sidney; Alessandro Sette
Journal:  Immunogenetics       Date:  2013-02-08       Impact factor: 2.846

10.  Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients.

Authors:  A Valli; A Sette; L Kappos; C Oseroff; J Sidney; G Miescher; M Hochberger; E D Albert; L Adorini
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.